Your session is about to expire
← Back to Search
Atorvastatin for Mild Cognitive Impairment
Study Summary
This trial will test whether atorvastatin can improve blood flow to the brain in people with mild cognitive impairment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with dementia in the past or have a history of dementia.I haven't taken statins in the last 6 months.I am a transplant patient on cyclosporine.I have not had a stroke or heart attack in the last 6 months.Your cognitive test scores for memory, processing speed, executive function, and language are very low (more than 1.5 standard deviations below normal for your age and education).I am currently taking or have taken a statin in the past 6 months.You do not have cognitive or functional impairment caused by another neurological disease or confusion.You currently have a problem with drugs or alcohol.I have a history of HIV.You have mild cognitive impairment, which is when your ability to think and remember things is slightly reduced.You cannot have an MRI because you have a pacemaker, defibrillator, or other metal implants that are not compatible.I cannot take statin medications due to health reasons.
- Group 1: Atorvastatin 40 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this investigation currently welcome new participants?
"Clinicaltrials.gov confirms that this trial is in active recruitment, having first been made available to the public on May 21st 2021 and last updated October 12th 2022."
Has a trial of this kind been conducted previously?
"Atorvastatin Oral Tablet is a medication with an extensive research history. Merck Sharp & Dohme LLC initially sponsored the drug's introduction in 2005, where it was tested on 80 participants and subsequently accepted for Phase 4 clinical trials. Currently, there are 70 active studies of Atorvastatin Oral Table spanning 162 cities across 28 countries worldwide."
Who meets the requirements for inclusion in this research study?
"This medical trial has a limited capacity of 20 participants, aged between 60 and 95 years old, that have been clinically diagnosed with mild cognitive impairment (MCI). Other requirements include evidence suggesting the MCI is not caused by any other neurological conditions or delirium, memory scores lower than 1.5 standard deviations below appropriate norms for their age and education level, no signs of dementia in the patient's history, and an absence of statin usage within the past 6 months."
What are the known risks associated with Atorvastatin Oral Tablet consumption?
"Based on the evidence provided by phase 2 trials, our team at Power judged Atorvastatin Oral Tablet to be a safe medication with a rating of 2. While there is data affirming safety, efficacy has not yet been established."
What medical issues does Atorvastatin Oral Tablet typically treat?
"Atorvastatin Oral Tablet is regularly prescribed to treat lipidemias and has been seen to be effective in ameliorating postoperative thromboembolism, anginal pain, transient ischemic attack."
Does this examination admit participants that are over two decades of age?
"According to the study's inclusion criteria, only people between 60 and 95 years old are eligible. Furthermore, there are 29 trials for minors and 596 for seniors."
How many individuals are actively participating in this experiment?
"Affirmative, the information publicly available on clinicaltrials.gov shows that this medical trial is currently enrolling patients. This study was originally posted on May 21st 2021 and updated most recently October 12th 2022. The goal is to recruit 20 participants at one site."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Johns Hopkins University, Bayview Medical Center: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger